Q2 2026 13F · SEC CIK 1795097

Privium Fund Management B.V.

Asset managerFiled 2026-08-07 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $544.2M
Reported positions: 61
Top holdings a year, 3 yrs: +25.7%
Average holding period: 2.6 yrs

Privium Fund Management B.V. is an asset manager that reported 61 positions worth $544.2M in its Q2 2026 13F, filed 2026-08-07. Its largest holdings were Tesla Inc (TSLA, 17.6%), Shopify Inc (SHOP, 7.8%), Advanced Micro Devices Inc (AMD, 6.6%). A portfolio copying its top holdings returned 25.7% a year over the last 3 years, against 20.4% for the S&P 500.

Privium Fund Management B.V. holdings largest 50 of 61 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Privium Fund Management B.V. 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
TSLATesla Inc	17.6%	17.2%	228,000	+2.7%	$95.9M
SHOPShopify Inc	7.8%	10.1%	370,000	-9.1%	$42.2M
AMDAdvanced Micro Devices Inc	6.6%	2.6%	62,000	+0.0%	$36.0M
AMZNAmazon Com Inc	6.1%	5.4%	140,000	+12.0%	$33.4M
IONSIonis Pharmaceuticals Inc	4.7%	4.5%	319,924	+10.3%	$25.4M
SPOTSpotify Technology SA	4.6%	6.8%	55,000	-17.9%	$25.3M
PLTRPalantir Technologies Inc	4.3%	6.1%	200,000	+0.0%	$23.3M
ARWRArrowhead Pharmaceuticals in	3.5%	4.8%	234,222	-36.2%	$19.1M
OPENOpendoor Technologies Inc	3.3%	—	3,940,904	—	$18.2M
LMNDLemonade, Inc.	3.2%	3.3%	270,259	+5.9%	$17.6M
NVDANvidia Corporation	3.0%	2.9%	81,000	+0.0%	$16.2M
IRENIren Limited	2.9%	2.3%	340,150	+6.2%	$15.6M
QUREUniqure NV	2.8%	1.7%	328,322	-32.5%	$15.1M
CBRSCerebras Systems Inc	2.5%	—	60,500	—	$13.4M
ASTSAST SpaceMobile Inc	2.4%	2.5%	145,000	+0.0%	$12.9M
RAREUltragenyx Pharmaceutical in	2.1%	1.6%	338,800	-7.1%	$11.3M
ARQTArcutis Biotherapeutics Inc	1.9%	1.6%	399,367	+24.4%	$10.5M
BIIBBiogen Inc	1.9%	1.7%	48,400	+10.5%	$10.5M
PRQRProqr Thrapeutics N V	1.9%	1.8%	5,520,024	+1.0%	$10.3M
AXSMAxsome Therapeutics, Inc.	1.8%	2.1%	39,944	-32.0%	$9.8M
URGNUrogen Pharma Ltd	1.4%	0.9%	210,000	-11.8%	$7.7M
SPCXSpace Exploration Techn Corp	1.3%	—	40,000	—	$6.8M
DNLIDenali Therapeutics Inc Com	1.1%	1.0%	229,857	-9.8%	$5.9M
VRTXVertex Pharmaceuticals Inc	0.9%	1.1%	9,400	-17.2%	$4.7M
BMRNBiomarin Pharmaceutical Inc	0.8%	1.1%	75,000	-18.7%	$4.3M
KRYSKrystal Biotech Inc	0.8%	0.6%	11,170	+0.0%	$4.2M
ALNYAlnylam Pharmaceuticals Inc	0.6%	0.8%	11,372	-7.0%	$3.4M
VRDNViridian Therapeutics Inc	0.6%	0.7%	173,516	+0.0%	$3.2M
BNTXBiontech SE	0.5%	0.5%	30,100	+11.5%	$2.8M
HIMSHims & Hers Health Inc	0.5%	0.2%	80,000	+100.0%	$2.8M
MGTXMeiragtx Hldgs PLC	0.5%	0.4%	196,112	-7.5%	$2.6M
ABEVAmbev SA	0.5%	0.6%	802,167	-15.4%	$2.5M
SRPTSarepta Therapeutics Inc	0.5%	0.2%	136,500	+196.7%	$2.5M
CRSPCrispr Therapeutics AG	0.5%	0.4%	44,974	+4.9%	$2.5M
BEAMBeam Therapeutics Inc	0.4%	0.3%	70,282	+9.8%	$2.4M
ZLABZai Lab Ltd	0.4%	0.5%	122,189	-7.6%	$2.3M
MRNAModerna Inc	0.4%	0.3%	29,994	+0.0%	$2.1M
RNACCartesian Therapeutics Inc	0.3%	0.2%	151,675	-15.3%	$1.6M
MICCMagnum Ice Cream	0.3%	—	98,221	—	$1.5M
WVEWave Life Sciences Ltd	0.3%	0.4%	241,010	+0.0%	$1.4M
TSHATaysha Gene Therapies Inc	0.2%	0.2%	198,900	+9.3%	$1.4M
ZTSZoetis Inc	0.2%	—	17,322	—	$1.2M
FDMT4d Molecular Therapeutics in	0.2%	0.3%	90,110	-47.1%	$1.2M
FATEFate Therapeutics Inc	0.2%	—	414,311	—	$1.1M
LEGNLegend Biotech Corp	0.2%	—	35,400	—	$1.0M
RCKTRocket Pharmaceuticals Inc	0.2%	0.2%	244,146	+0.8%	$835K
NOVNov Inc	0.1%	0.2%	42,026	+0.0%	$780K
BTGB2gold Corp	0.1%	—	195,083	—	$730K
TTETotalenergies SE	0.1%	—	10,723	—	$729K
LXEOLexeo Therapeutics Inc	0.1%	0.2%	155,000	-24.4%	$722K

What Privium Fund Management B.V. bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +3.7% /yr; S&P 500 +20.1%
3 years: +25.7% /yr; S&P 500 +20.4%
5 years: +10.3% /yr; S&P 500 +13.0%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$544.2M	61
Q1 2026	$480.3M	60
Q4 2025	$543.1M	57
Q3 2025	$556.3M	59
Q2 2025	$463.5M	55
Q1 2025	$383.6M	56
Q4 2024	$441.9M	64
Q3 2024	$402.0M	82
Q2 2024	$392.1M	129
Q1 2024	$374.5M	117
Q4 2023	$359.0M	114
Q3 2023	$336.2M	115

Questions about Privium Fund Management B.V.'s portfolio

What stocks does Privium Fund Management B.V. own?

Privium Fund Management B.V.'s latest 13F, for Q2 2026 and filed Aug 7, 2026, lists 61 positions worth $544.2M. The largest are Tesla Inc (TSLA) at 17.6%, Shopify Inc (SHOP) at 7.8%, Advanced Micro Devices Inc (AMD) at 6.6%, Amazon Com Inc (AMZN) at 6.1% and Ionis Pharmaceuticals Inc (IONS) at 4.7%.

What did Privium Fund Management B.V. buy last quarter?

In Q2 2026, Privium Fund Management B.V. added Sarepta Therapeutics Inc (SRPT) (+196.7% shares), Hims & Hers Health Inc (HIMS) (+100.0% shares) and Arcutis Biotherapeutics Inc (ARQT) (+24.4% shares), compared with its Q1 2026 filing.

What did Privium Fund Management B.V. sell last quarter?

In Q2 2026, Privium Fund Management B.V. cut from its top 50 Coinbase Global Inc (COIN), cut from its top 50 Sea Ltd (SE), cut from its top 50 Esperion Therapeutics Inc Ne (ESPR), cut from its top 50 enGene Holdings Inc. (ENGN), cut from its top 50 Stoke Therapeutics Inc (STOK), 4d Molecular Therapeutics in (FDMT) (-47.1% shares), Arrowhead Pharmaceuticals in (ARWR) (-36.2% shares) and Uniqure NV (QURE) (-32.5% shares), compared with its Q1 2026 filing.

How has Privium Fund Management B.V.'s portfolio performed?

A portfolio copying Privium Fund Management B.V.'s 20 largest 13F holdings each quarter, from the day each filing was public, returned +25.7% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: +3.7% against +20.1%. Over 5 years: +10.3% a year against +13.0%.

When is Privium Fund Management B.V.'s next 13F filing due?

13F filings are due 45 days after each quarter ends. Privium Fund Management B.V.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.